W. O'Riordan

发表

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

S. Solomon, M. Sweetser, Y. Parman, 2018, The New England journal of medicine.

Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection

J. Almenoff, W. O'Riordan, J. M. Davenport, 2011, Antimicrobial Agents and Chemotherapy.

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

V. Fowler, S. Wilson, W. O'Riordan, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.

W. O'Riordan, P. Prokocimer, C. D. De Anda, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection

M. Wilcox, W. O'Riordan, H. Ye, 2019, Antimicrobial Agents and Chemotherapy.

A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study

S. Simeonov, Y. Cho, Seong-Ho Choi, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients

M. Ison, B. O'Neil, J. Fraiz, 2014, Antiviral therapy.

Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, Teri Ashton, E. Dumont, 2017, Antimicrobial Agents and Chemotherapy.

Safety, Tolerability, and Efficacy of GSK1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, O. Naderer, R. Corey, 2014, Antimicrobial Agents and Chemotherapy.

Safety , Tolerability , and Efficacy of GSK 1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, O. Naderer, R. Corey, 2014 .

Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis.

V. Fowler, R. Streilein, R. Gallo, 2007, The Journal of infectious diseases.

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

E. Nordh, Yi-Chung Lee, R. Sommerville, 2020, Lancet Neurology.

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

J. Kort, Sandra S. Lovell, W. O'Riordan, 2015, Antimicrobial Agents and Chemotherapy.

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

J. Miro, V. Fowler, W. O'Riordan, 2014, BMC Infectious Diseases.

Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.

W. O'Riordan, G. Corey, S. Barriere, 2012, The Journal of antimicrobial chemotherapy.

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

W. O'Riordan, G. Corey, G. Moeck, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.

S. Wilson, W. O'Riordan, S. Barriere, 2009, American journal of surgery.

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

J. Lieske, D. Magen, M. Sweetser, 2021, The New England journal of medicine.

A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections.

S. Cammarata, W. O'Riordan, L. Lawrence, 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

V. Fowler, W. O'Riordan, J. Morganroth, 2006, Antimicrobial Agents and Chemotherapy.

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

W. O'Riordan, D. Krievins, Ž. Endzinas, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

V. Fowler, C. Cabell, W. O'Riordan, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Single-dose oritavancin in the treatment of acute bacterial skin infections.

W. O'Riordan, G. Corey, G. Moeck, 2014, The New England journal of medicine.

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

T. File, A. Torres, M. Wilcox, 2018, Antimicrobial Agents and Chemotherapy.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

M. Dudley, W. O'Riordan, G. Corey, 2018, Antimicrobial Agents and Chemotherapy.